UPDATE: JPMorgan Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
Tweet Send to a Friend
(Updated - June 21, 2022 7:15 AM EDT)
JPMorgan analyst Cory Kasimov downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Cory Kasimov downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE